BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 27216253)

  • 21. Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
    Lertjanyakun V; Chaiyakunapruk N; Kunisawa S; Imanaka Y
    Pharmacoeconomics; 2018 Sep; 36(9):1113-1124. PubMed ID: 29707743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2- Advanced Breast Cancer From a US Payer Perspective.
    Xie J; Hao Y; Zhou ZY; Qi CZ; De G; Glück S
    Clin Breast Cancer; 2015 Oct; 15(5):e263-76. PubMed ID: 26048087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.
    Hartkopf AD; Huober J; Volz B; Nabieva N; Taran FA; Schwitulla J; Overkamp F; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Lux MP; Lüftner D; Wallwiener M; Müller V; Beckmann MW; Belleville E; Wimberger P; Hielscher C; Geberth M; Fersis N; Abenhardt W; Kurbacher C; Wuerstlein R; Thomssen C; Untch M; Fasching PA; Janni W; Fehm TN; Wallwiener D; Brucker SY; Schneeweiss A
    Breast; 2018 Feb; 37():42-51. PubMed ID: 29100043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer.
    DeMichele A; Robert N; Chen C; Kim S; Zhang Z; Lu DR; Aguilar KM; Wang Y; Li B; Schneeweiss S; Rassen JA; Gaffney M; McRoy L
    Target Oncol; 2023 Jul; 18(4):543-558. PubMed ID: 37428347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
    Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
    Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.
    Burne R; Balu S; Guérin A; Bungay R; Sin R; Paul ML
    J Med Econ; 2021; 24(1):806-815. PubMed ID: 34098827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.
    Campone M; Yang H; Faust E; Kageleiry A; Signorovitch JE; Zhang J; Gao H
    J Med Econ; 2014 Dec; 17(12):837-45. PubMed ID: 25164472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
    Xie J; Diener M; De G; Yang H; Wu EQ; Namjoshi M
    J Med Econ; 2013; 16(2):278-88. PubMed ID: 23153318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.
    Kourlaba G; Rapti V; Alexopoulos A; Relakis J; Koumakis G; Chatzikou M; Maniadakis N; Georgoulias V
    BMC Health Serv Res; 2015 Aug; 15():307. PubMed ID: 26239115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
    Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer.
    Hao Y; Lin PL; Xie J; Li N; Koo V; Ohashi E; Wu EQ; Rogerio J
    J Comp Eff Res; 2015 Aug; 4(4):315-26. PubMed ID: 26274793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries.
    Irwin DE; Masaquel A; Johnston S; Barnett B
    J Med Econ; 2016 Nov; 19(11):1027-1033. PubMed ID: 27206801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
    Subramanian J; Fernandes AW; Laliberté F; Pavilack M; DerSarkissian M; Duh MS
    Lung Cancer; 2019 Dec; 138():131-138. PubMed ID: 31733614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
    O'Shaughnessy J; Thaddeus Beck J; Royce M
    Cancer Treat Rev; 2018 Sep; 69():204-214. PubMed ID: 30092555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan.
    Lewis L; Taylor M; Suriya Ertugyrovna Y; Kuanysh Shadybayevich N; Kaldygul Kabakovna S; Ramil Zufarovich A
    J Med Econ; 2015 Mar; 18(3):189-99. PubMed ID: 25415641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
    Chen XL; Du F; Hong RX; Wang JY; Luo Y; Li Q; Fan Y; Xu BH
    Chin J Cancer; 2016 Apr; 35():39. PubMed ID: 27112139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic Breast Cancer Harboring Altered PI3K/AKT/mTOR.
    Wang R; Zhu QY; Ye WW; Huang Y; Chen ZH; Zheng YB; Zou X; Wang J; Jiang DL; Wang XJ; Xu ZY; Cao WM
    Discov Med; 2024 Mar; 36(182):527-537. PubMed ID: 38531793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer.
    Dalal AA; Gagnon-Sanschagrin P; Burne R; Guérin A; Gauthier G; Small T; Niravath P
    Adv Ther; 2018 Jun; 35(6):768-778. PubMed ID: 29869106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-line treatment disruption among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.
    Tang DH; Li N; Du EX; Peeples M; Chu L; Xie J; Barghout V
    Curr Med Res Opin; 2017 Dec; 33(12):2137-2143. PubMed ID: 28994315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study.
    Li N; Hao Y; Xie J; Lin PL; Koo V; Ohashi E; Wu EQ
    Int J Breast Cancer; 2015; 2015():240750. PubMed ID: 26078883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.